Equities research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for MoonLake Immunotherapeutics in a ...

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

H.C. Wainwright downgraded Geron (GERN) to Neutral from Buy without a price target following the Q4 report. The shift in guidance for interim ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy recommendation. As of February 19, 2025, the average one-year price target ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (LSE:0LP5) with a Buy recommendation. As of January 29, 2025, the average one-year price target for ...